October 2025 – Page 2

WuXi AppTec Divests China Clinical Services to Hillhouse Capital, Refocuses on Manufacturing Business

4 weeks ago talkbio0Tagged China, Clinical, clinical research services, CRDMO, Divestment, Hillhouse Capital, Manufacturing, WuXi, WuXi AppTec

WuXi AppTec; Hillhouse Capital; divestment; clinical research services; CRDMO; manufacturing; China; WuXi Clinical; MedKey

Lilly Commits $1.2 Billion to Expand GLP-1 Pill Manufacturing Facility in Puerto Rico

4 weeks ago talkbio0Tagged Carolina, eli lilly, expansion, Investments, Manufacturing, Oral Medicine, orforglipron, pharmaceutical production, Product containing glucagon-like peptide 1 receptor agonist (product), Puerto Rico, supply chain, United States

Eli Lilly; Puerto Rico; GLP-1 receptor agonist; orforglipron; manufacturing expansion; oral medicines; investment; Carolina; pharmaceutical production; U.S. supply chain

WuXi AppTec Sells China-Based Clinical Research Units to Hillhouse Investment Management

4 weeks ago talkbio0Tagged China-based, Clinical, Clinical Services, CRDMO, Hillhouse Investment Management, MedKey, Sales - occupational activity, WuXi, WuXi AppTec

WuXi AppTec; clinical services; China-based; sale; Hillhouse Investment Management; WuXi Clinical; WuXi MedKey; CRDMO strategy

AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

4 weeks ago talkbio0Tagged AH 001, AI-designed drug, Alopecia, Androgenetic Alopecia, AnHorn Medicines, Generative AI, Phase I Clinical Trials, protein degrader, Safety, tolerability

AH-001; AI-designed drug; Phase I clinical trial; safety; tolerability; androgenetic alopecia; protein degrader; AnHorn Medicines; generative AI; hair loss

Viking Therapeutics to Highlight VK2735 Clinical Data at ObesityWeek 2025

4 weeks ago talkbio0Tagged Clinical Data, Clinical Trials, GLP-1/GIP Dual Agonist, Metabolic Syndrome X, Obesity, ObesityWeek 2025, Prediabetes syndrome, VANQUISH-1, venture, Viking Therapeutics, VK2735

Viking Therapeutics; VK2735; ObesityWeek 2025; VENTURE trial; VANQUISH-1 trial; GLP-1/GIP dual agonist; clinical data; obesity; prediabetes; metabolic syndrome

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

4 weeks ago talkbio0Tagged Biotechnology, Collaboration, Immunology, Metabolic Diseases, milestone payments, ModeX, MSTAR, multispecific antibodies, Neoplasms, OPKO Health, Regeneron, upfront payment

Regeneron; ModeX Therapeutics; multispecific antibodies; MSTAR platform; biotechnology deal; upfront payment; milestone payments; immunology; oncology; metabolic diseases; collaboration; OPKO Health